FDA-cleared blood test empowers local doctor’s office diagnosis
For millions of families navigating the slow, terrifying decline that accompanies Alzheimer’s disease, the greatest struggle has always been uncertainty.
By Caroline Ashford ·
eli lilly — Lorien Times
Eli Lilly's Foundayo cleared by MHRA; NHS needs NICE approval
The press release futurism is exhausting. It always smells like a breakthrough—a pill, an implant, some algorithm that promises to make the messy, inefficient reality of human biology frictionless.
By Imani Sutton ·
The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
The market for weight loss drugs—a $100 billion prize by the 2030s—is not merely growing; it is demanding ruthless efficiency.
By Bram de Vries ·
Eli Lilly’s Mounjaro revenue is just modern-day oil money extraction
The quarterly earnings report is supposed to tell us about market health; instead, it’s another flashing neon sign of where America's care infrastructure has failed—and who gets rich from it.
By Josie Calloway ·
Lilly's $87 billion growth exceeds the scope of Congress or FDA
Eli Lilly’s Q2 2026 report isn't just a good quarter; it’s an inflection point that demands more than celebratory headlines.
By Nikhil Raghavan ·